OmniAb (OABI) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

OmniAb (OABI) overview

OmniAb (OABI) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 18.7m and operating profit of USD -69.0m; the year-end share price was 1.85 USD and market capitalisation was USD 267m. OmniAb is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get OmniAb's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 267mFY 2025
Share price1.85 USDFY 2025 year end
RevenueUSD 18.7mFY 2025
Operating profitUSD -69.0mFY 2025
Net earningsUSD -64.8mFY 2025
Market capitalisationUSD 267mFY 2025 year end

About OmniAb

OmniAb licenses antibody discovery technologies to pharmaceutical and biotechnology companies and academic institutions. Its platform uses engineered transgenic animals, screening methods, sequencing data, and computational tools to identify antibodies and other target-binding proteins for therapeutic development. The company offers integrated discovery services and customizable technology options, including systems for generating human antibodies and approaches supporting bispecific antibodies, peptides, and other antibody-based therapeutic formats.

Generate the OmniAb report

OmniAb is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for OmniAb and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on OmniAb

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.